eXoZymes (NASDAQ:EXOZ - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, Zacks reports.
eXoZymes Stock Performance
NASDAQ:EXOZ traded down $0.29 during midday trading on Friday, reaching $9.70. The stock had a trading volume of 486 shares, compared to its average volume of 4,225. The business's fifty day simple moving average is $10.45. eXoZymes has a 12-month low of $8.50 and a 12-month high of $23.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.19 and a quick ratio of 6.19.
About eXoZymes
(
Get Free Report)
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Further Reading
Before you consider eXoZymes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and eXoZymes wasn't on the list.
While eXoZymes currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
